Investigating Combinations in Cancer Research

May 31, 2018

T

he tumor microenvironment contains multiple immune pathways which can be manipulated by a tumor to evade immune response. In most cases, tumors use more than one immune suppression mechanism, or develop new mechanisms over the course of the disease, which means we will need a variety of different approaches to address a patient’s specific tumor biology.

At Bristol-Myers Squibb, we are investigating how potentially complementary signaling pathways interact and, through our research, are exploring ways to leverage the complex tumor microenvironment to reset and optimize anti-tumor immunity.

Explore the articles below to learn more about the science behind the tumor microenvironment and the immune system. Also read about the potential of combinations in cancer therapy and the need for partnering with collaborators in order to advance the science as quickly as possible.

Immune Biomarkers in Oncology Research

A Combination Approach: Growing the Oncology Pipeline Through Innovation and Collaboration

Every day, we are working with partners to uncover important information about the complex tumor microenvironment and its intersection with the immune system, which then informs our deliberately-built pipeline.

Igniting the Tumor Microenvironment

Igniting the Tumor Microenvironment

Scientists continue to research ways to harness the immune system to tackle cancer through multiple mechanisms and pathways.

Immune Biomarkers in Oncology Research

Interactive I-O Pathway Wheel

We're investigating specific categories of immune mechanisms that can help restore the body's natural ability to fight cancer, as well as complementary signaling pathways that may help activate an antitumor immune response.

The I-O Quest

Exploring the research behind why some people respond to immunotherapy and others don’t.

Translational Medicine: Leveraging Bioinformatics Play Icon

Leveraging Bioinformatics

Hear from Joe Szustakowski, head of translational bioinformatics, about how his team uses raw data and distills that into a useful biological signals.

Right Treatment, Right Patient, Right Time

Through our research into the tumor microenvironment, we are learning more about how a patient’s dynamic tumor biology can be used as a guide for treatment decisions throughout his or her cancer journey. We continue to investigate the role of PD-L1 , tumor mutational burden , and gene signatures of inflammation, and other potentially predictive biomarkers – both tumor and peripheral biomarkers – to better inform and predict the benefit of current and future approaches. Additionally, our teams continue to evaluate potential diagnostic tools to help identify those biomarkers in patients leveraging less-invasive methods such as liquid biopsy.

To learn more about how Bristol-Myers Squibb is exploring the research behind why some people respond to immunotherapy and others do not, click here. 

Related Links